Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.310 -0.200 (-4.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals
Via Benzinga
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
They might not be profitable yet, but they're swinging for the fences. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI Surge Ending: Only One Category Was Up This Week
Six of the 7 categories we cover dropped this week, compared with 3 in March. The data clearly indicates that the surge in this sector is stalling or perhaps is even over. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
This stock's upside is huge, but so is its downside. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Forecasting The Future: 4 Analyst Projections For Recursion Pharmaceuticals
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
AI Sector Stalling: Only 4 Of 7 Categories Went Up In March
No AI category went down in February, but 3 did in March - confirming my comment last week that 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Invest Continues To Double Down On Moderna, Sells Nvidia Shares
Via Benzinga
Recursion Publishes Annual Environmental, Social and Governance Report
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact. 
From Recursion Pharmaceuticals
Via GlobeNewswire
Nvidia's AI Revolution Is Transforming Healthcare with Johnson & Johnson and GE Healthcare Partnerships
Nvidia announces partnerships with J&J and GE Healthcare to integrate generative AI into surgery and medical imaging at GTC AI conference. Analysts see potential for revenue growth outside tech sector.... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
New COVID-Like Outbreak 'Matter Of When, Not If,' WHO Director Warns As Scientists Race To Prepare Using Artificial Intelligence
Via Benzinga
Nvidia's Secret Weapon Is Not Just Chips But Investing $1.5B In AI's Rising Stars: Report Unveils CEO Jensen Huang's 10-Year Vision
Additionally, the investments help Nvidia "build out the future ecosystem of businesses that depend on its technology" even as rivals are trying to break into the chipmaker's dominance. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Announces Plans to Open New Office in London
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the... 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
The company just made a provocative move in one of its collaborations. 
Via The Motley Fool
The Top 7 Small-Cap Stocks to Buy in March 2024
These top small-cap stocks to buy are set for a strong 2024 as reduced inflation increases their growth prospects. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
Many healthcare stocks have extremely bright outlooks and very low valuations. Here are three top healthcare stocks to buy. 
Via InvestorPlace
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Grand View Research says the global 
Via Talk Markets
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks. 
Via InvestorPlace
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Recursion Pharmaceuticals Stock Dived by Nearly 17% Today
The company had attracted much interest due to its heavy use of artificial intelligence, but its latest fundamentals disappointed many. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket
Shares of Beyond Meat, Inc. (NASDAQ: BYND) rose sharply in today’s pre-market trading as the company reported stronger-than-expected sales for its fourth quarter. 
Via Benzinga
3D Systems Posts Downbeat Q4 Results, Joins Eventbrite, Lemonade And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. 
Via Benzinga
What's Going On With Recursion Pharmaceuticals Stock Tuesday?
Recursion reported fourth-quarter revenue of $10.89 million, which missed the consensus estimate of $20.35 million. The clinical stage biotech company reported a quarterly loss of 42 cents per share,... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
10+ Stocks, ETFs To Ride On Nvidia's Record-Breaking Success
Shares of NVIDIA Corp rose 15% as quarterly earnings beat forecasts. CEO cites AI's role in company's growth. Tech sector up. ETFs benefit. 
Via Benzinga
Topics Artificial Intelligence ETFs Earnings
Exposures Artificial Intelligence Financial
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.